Bristol Myers Squibb - News
WEBStay updated on the latest news from Bristol Myers Squibb, a global biopharmaceutical company dedicated to developing and delivering innovative medicines for serious diseases.
Bristol Myers Squibb - News
WEBSep 18, 2024 · Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEBSep 26, 2024 · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. 1 COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating ...
FDA approves Bristol Myers Squibb's schizophrenia drug
WEB6 days ago · The Food and Drug Administration approved Bristol Myers Squibb’s highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more ...
Bristol Myers Squibb Presents New Data from Two Trials …
WEB6 days ago · About Bristol Myers Squibb. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over ...
Bristol Myers to Acquire the Drugmaker Karuna for $14 Billion
WEBDec 22, 2023 · Bristol Myers Squibb, the global pharmaceutical giant, said on Friday that it would acquire Karuna Therapeutics, which makes drugs to treat schizophrenia and Alzheimer’s, in an all-cash deal...
Absence of Black Box Warning For Bristol Myers' Schizophrenia …
WEB6 days ago · On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
US FDA approves Bristol Myers' schizophrenia drug - MSN
WEBStory by Reuters. • 2d. (Reuters) -The U.S. FDA approved Bristol Myers Squibb's schizophrenia drug on Thursday, providing patients with a treatment option that reduces symptoms of the mental ...
News and media - Bristol Myers Squibb
WEBVisit the Bristol Myers Squibb newsroom & stay up to date with our most current news as we continue to make a difference in the lives of our patients.
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
WEB3 days ago · Sept 30 (Reuters) - Bristol Myers Squibb (BMY.N) won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer ...